112030-48-5

Basic information

• Product Name: 3-(4-methoxyphenyl)-2H-benzo[b][1,4]oxazine
• Synonyms: 3-(4-methoxyphenyl)-2H-benzo[b][1,4]oxazine
• CAS NO: 112030-48-5
• Molecular Weight: 239.274
• Mol File: 112030-48-5.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: 3-(4-methoxyphenyl)-2H-benzo[b][1,4]oxazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-methoxyphenyl)-2H-benzo[b][1,4]oxazine(112030-48-5)
• EPA Substance Registry System: 3-(4-methoxyphenyl)-2H-benzo[b][1,4]oxazine(112030-48-5)

Safety Data

• Hazardous Substances Data: 112030-48-5(Hazardous Substances Data)

Upstream product

• 95-55-6 2-amino-phenol 
• 2632-13-5 2-Bromo-4'-methoxyacetophenone 
• 74413-02-8 1-(4-methoxyphenyl)-2-(2-nitrophenoxy)ethanone 
• 88-75-5 2-hydroxynitrobenzene 
• 2196-99-8 2-chloro-1-(4-methoxyphenyl)ethanone 

Relevant articles and documents

Kinetic Resolution by Lithiation: Highly Enantioselective Synthesis of Substituted Dihydrobenzoxazines and Tetrahydroquinoxalines

Kinetic resolution provided a highly enantioselective method to access a range of 3-aryl-3,4-dihydro-2H-1,4-benzoxazines using n-butyllithium and the chiral ligand sparteine. The enantioenrichment remained high on removing the tert-butoxycarbonyl (Boc) protecting group. The intermediate organolithium undergoes ring opening to an enamine. The kinetic resolution was extended to give enantiomerically enriched substituted 1,2,3,4-tetrahydroquinoxalines and was applied to the synthesis of an analogue of the antibiotic levofloxacin that was screened for its activity against the human pathogen Streptococcus pneumoniae.

Rhodium-Catalyzed Spiro Indenyl Benzoxazine Synthesis via C-H Activation/Annulation of 3-Aryl-2H-Benzo[b][1,4]oxazines and Alkynes

The rhodium (III)-catalyzed annulation of 3-Aryl-2H-Benzo[b][1,4]oxazines with alkynes via C–H activation has been developed. This reaction afforded a series of spiro indenyl benzoxazine in high yields under mild reaction condition with good functional group tolerance.

Searching for Novel Inhibitors of the S. aureus NorA Efflux Pump: Synthesis and Biological Evaluation of the 3-Phenyl-1,4-benzothiazine Analogues

Bacterial resistance to antimicrobial agents has become an increasingly serious health problem in recent years. Among the strategies by which resistance can be achieved, overexpression of efflux pumps such as NorA of Staphylococcus aureus leads to a sub-lethal concentration of the antibacterial agent at the active site that in turn may predispose the organism to the development of high-level target-based resistance. With an aim to improve both the chemical stability and potency of our previously reported 3-phenyl-1,4-benzothiazine NorA inhibitors, we replaced the benzothiazine core with different nuclei. None of the new synthesized compounds showed any appreciable intrinsic antibacterial activity, and, in particular, 2-(3,4-dimethoxyphenyl)quinoline (6 c) was able to decrease, in a concentration-dependent manner, the ciprofloxacin MIC against the norA-overexpressing strains S. aureus SA-K2378 (norA++) and SA-1199B (norA+/A116E GrlA).